TY  - JOUR
A1  - Xie, Fei
A1  - Ye, Lin
A1  - Chang, Judy C.
A1  - Beyer, Ashley I.
A1  - Wang, Jiaming
A1  - Muench, Marcus O.
A1  - Kan, Yuet Wai
T1  - Seamless gene correction of β-thalassemia mutations in patient-specific iPSCs using CRISPR/Cas9 and piggyBac
Y1  - 2014/09/01 
JF  - Genome Research 
JO  - Genome Research 
SP  - 1526 
EP  - 1533 
DO  - 10.1101/gr.173427.114 
VL  - 24 
IS  - 9 
UR  - http://genome.cshlp.org/content/24/9/1526.abstract 
N2  - β-thalassemia, one of the most common genetic diseases worldwide, is caused by mutations in the human hemoglobin beta (HBB) gene. Creation of human induced pluripotent stem cells (iPSCs) from β-thalassemia patients could offer an approach to cure this disease. Correction of the disease-causing mutations in iPSCs could restore normal function and provide a rich source of cells for transplantation. In this study, we used the latest gene-editing tool, CRISPR/Cas9 technology, combined with the piggyBac transposon to efficiently correct the HBB mutations in patient-derived iPSCs without leaving any residual footprint. No off-target effects were detected in the corrected iPSCs, and the cells retain full pluripotency and exhibit normal karyotypes. When differentiated into erythroblasts using a monolayer culture, gene-corrected iPSCs restored expression of HBB compared to the parental iPSCs line. Our study provides an effective approach to correct HBB mutations without leaving any genetic footprint in patient-derived iPSCs, thereby demonstrating a critical step toward the future application of stem cell-based gene therapy to monogenic diseases. 
ER  -